UB Paderborn / Katalog / Suche / in CDI

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-06, Vol.17 (6), p.e0264741-e0264741

2022

Link zum Volltext

Verfügbarkeit prüfen

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Liver international, 2020-03, Vol.40 (3), p.539-548

2020

Link zum Volltext

Verfügbarkeit prüfen

Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors

Transplantation, 2002-02, Vol.73 (3), p.386

2002

Link zum Volltext

Verfügbarkeit prüfen

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Biomedicines, 2021-10, Vol.9 (10), p.1495

2021

Link zum Volltext

Verfügbarkeit prüfen

Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis

Clinical science (1979), 2003-09, Vol.105 (3), p.373

2003

Link zum Volltext

Verfügbarkeit prüfen

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Link zum Volltext

Verfügbarkeit prüfen

Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis

Clinical endocrinology (Oxford), 2009-01, Vol.70 (1), p.60-65

2009

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)

European journal of gastroenterology & hepatology, 2019-11, Vol.31 (11), p.1424

2019

Link zum Volltext

Verfügbarkeit prüfen

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Zeitschrift fur Gastroenterologie, 2021-03, Vol.59 (3), p.241

2021

Link zum Volltext

Verfügbarkeit prüfen

Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C

Liver international, 2003-12, Vol.23 (6), p.420-425

2003

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C

Clinica chimica acta, 2002-02, Vol.316 (1), p.71-81

2002

Link zum Volltext

Verfügbarkeit prüfen

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study

PloS one, 2016-07, Vol.11 (7), p.e0159976

2016

Link zum Volltext

Verfügbarkeit prüfen

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2019-01, Vol.57 (1), p.27

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT 1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Link zum Volltext

Verfügbarkeit prüfen

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting

PloS one, 2015-12, Vol.10 (12), p.e0145622-e0145622

2015

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-01, Vol.17 (6)

2022

Link zum Volltext

Verfügbarkeit prüfen

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)

Substance abuse : research and treatment, 2019, Vol.13, p.1178221819835847-1178221819835847

2019

Link zum Volltext

Verfügbarkeit prüfen

Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C

Journal of hepatology, 2001-02, Vol.34 (2), p.239-247

2001

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV

Journal of hepatology, 2006-12, Vol.45 (6), p.770-778

2006

Link zum Volltext

Verfügbarkeit prüfen

Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis

American journal of physiology: Gastrointestinal and liver physiology, 2009-02, Vol.296 (2), p.G196-G201

2009

Link zum Volltext

Verfügbarkeit prüfen

Plasma bile acids are not associated with energy metabolism in humans

Nutrition & metabolism, 2010-09, Vol.7 (1), p.73-73, Article 73

2010

Link zum Volltext

Verfügbarkeit prüfen

Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance

American journal of physiology: endocrinology and metabolism, 2006-08, Vol.291 (2), p.E199-E206

2006

Link zum Volltext

Verfügbarkeit prüfen

Expression of Matrix Metalloproteinase-2 and -9 and Their Inhibitors in Peripheral Blood Cells of Patients with Chronic Hepatitis C

Clinical chemistry (Baltimore, Md.), 2000-02, Vol.46 (2), p.183-192

2000

Link zum Volltext

Verfügbarkeit prüfen

Treatment of acute liver failure

Metabolic brain disease, 2001-06, Vol.16 (1-2), p.103-117

Boeker, K H

2001

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Decreased hepatic RBP4 secretion is correlated with reduced hepatic glucose production but is not associated with insulin resistance in patients with liver cirrhosis

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C

Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C

Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT 1 patients

Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)

Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C

Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV

Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis

Plasma bile acids are not associated with energy metabolism in humans

Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance

Expression of Matrix Metalloproteinase-2 and -9 and Their Inhibitors in Peripheral Blood Cells of Patients with Chronic Hepatitis C

Treatment of acute liver failure

Suchergebnisse filtern